Search results
... Performing Large-Cap Stocks Last Week (May 20-May 26, 2024): Are They In Your Portfolio? -...
Benzinga· 1 hour agoAre they in your portfolio? First Solar, Inc. FSLR shares jumped 41.5% possibly in response to...
Should You Buy This Stock After a Regulatory Setback?
The Motley Fool via AOL· 5 hours agoThough the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting...
The Moderna News That Has MRNA Stock Price Surging This Week: 3 Key Catalysts
InvestorPlace· 3 days agoModerna (NASDAQ:MRNA) stock is up more than 20% in just the past five trading sessions as investors foresee strong growth opportunities for the biotechnology ...
Why is Moderna stock up 10% on Wednesday?
Invezz· 4 days agoModerna Inc (NASDAQ: MRNA) is up more than 10% on Wednesday after a child tested positive for avian influenza in Australia. Are you looking for signals &...
Moderna Has Big AI News. Is the Stock a Buy?
Motley Fool via Yahoo Finance· 4 days ago*Stock Advisor returns as of May 13, 2024 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends International Business...
Robeco Institutional Asset Management B.V. Decreases Stake in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 5 days ago(NASDAQ:MRNA – Free Report) by 51.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 68,889 shares of the company’s < ...
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb - Moderna (NASDAQ:MRNA)
Benzinga· 4 days agoShares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease...
Vaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines By Investing.com
Investing.com· 3 days agoVaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 2 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
Arcturus Therapeutics’ (ARCT) Outperform Rating Reaffirmed at William Blair
ETF DAILY NEWS· 2 days agoARCT has been the topic of a number of other research reports. Canaccord Genuity Group...lowered their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a buy rating ...